SCREENING NOVEL FUNGI AGAINST ADRIAMYCIN-RESISTANT L1210

筛选抗阿霉素 L1210 的新型真菌

• 批准号: 3491550
• 负责人: BARRY A KATZ
• 金额: $ 5万
• 依托单位: MYCOSEARCH, INC.
• 依托单位国家: 美国
• 财政年份: 1986
• 资助国家: 美国
• 起止时间: 1986-09-15 至 1987-03-14
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/3491550
• 关键词: Ascomycetes; Basidiomycetes; Fungi Imperfecti; antineoplastic antibiotics; biotechnology; doxorubicin; drug resistance; drug screening /evaluation; microorganism; microorganism culture

A literature review of fungally-derived antitumor agents reveals that the fungi constitute a group of easiliy collected species, indigenous to Western Europe, the eastern U.S. and Japan. Their availability may have been the decisive factor in these drug discoveries. Significantly, their habitat ranges are broad and suggest that other saprophytic and parasitic fungi, worldwide, could have developed distinctive antitumor agents, also. MYCOsearch, through is proprietary fungal isolation techniques and systematic collecting, already has many unique and unusual fungi in its collection. No NCI support is requestd for fungus collecting. We propose to screen representative isolates of at least 100 selected tropical and temperate forest taxa. Broths and agar cultures would be screened against an Adriamycin-resistant tumor cell culture, perhaps L1210, in vitro, using a rapid assay. Parallel antifungal screens would be performed. Dr. J.B. Tunac will be an active consultant to ensure the high quality of the screening effort. All positive cultures would be available to NCI for further screening against human tumor lines. Results may suggest whether additional screening of novel fungi is warranted. Phase II research would involve further primary screening and purification of the antitumor agents from fungi.

真菌源性抗肿瘤药物的文献综述表明， 真菌是一组容易采集的物种，是原产于 西欧、美国东部和日本。 他们的可用性可能有 是这些药物发现的决定性因素。 值得注意的是，他们的 栖息地范围广泛，表明其他腐生和寄生生物 世界范围内的真菌也可能开发出独特的抗肿瘤剂。 MYCOsearch，通过专有的真菌分离技术和 系统性采集，已拥有许多独特、不寻常的真菌 收藏。 真菌采集无需 NCI 支持。 我们建议 筛选至少 100 个选定的热带和 温带森林类群。 肉汤和琼脂培养物将进行筛选 体外阿霉素耐药肿瘤细胞培养物，可能是 L1210，使用 快速测定。 将进行平行的抗真菌筛选。 J.B.博士 Tunac 将成为一名积极的顾问，以确保项目的高质量 筛选工作。 所有阳性培养物都将提供给 NCI 针对人类肿瘤系的进一步筛选。 结果可能表明是否 有必要对新型真菌进行额外筛选。 第二阶段研究将 涉及抗肿瘤药物的进一步初步筛选和纯化 来自真菌。